Relmada Therapeutics: delivering medicines for depression and central nervous system disorders

Relmada Therapeutics is developing REL-1017, a phase 2, noncompetitive N-methyl-D-aspartate receptor antagonist for the treatment of depression and Rett syndrome.

Like Comment
Page of
Go to the profile of Relmada Therapeutics Inc.

Relmada Therapeutics Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines for high unmet medical needs in the treatment of central nervous system diseases. REL-1017 (dextromethadone), Relmada’s lead asset, is an orally administered non-competitive NMDA receptor (NMDAR) antagonist, which binds the NMDAR ketamine binding site. REL-1017 has demonstrated an overall favorable safety profile without psychotomimetic and dissociative adverse reactions in two Phase 1 studies. In preclinical studies, REL-1017 showed antidepressant efficacy and effects on neuronal activity similar to that of ketamine. The U.S. Food and Drug Administration previously granted Fast Track designation for dextromethadone for the adjunctive treatment of MDD. Relmada is currently evaluating REL-1017 in a Phase 2 clinical trial assessing tolerability, safety and antidepressant efficacy in patients with treatment resistant depression. Results are expected in mid 2019.

No comments yet.